SNMMI 2025 radium-223-treated patients, REASSURE study, metastatic castration-resistant prostate cancer (mCRPC), ALSYMPCA trial, safety of radium-223 in patients with mCRPC.

Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based ...

Philipp Backhaus presented first-in-human data on [⁶⁸Ga]Ga-OncoACP3-DOTA PET imaging, targeting prostatic acid phosphatase (ACP3), a novel and promising theranostic marker for prostate cancer.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New ...

United Imaging Highlights Breakthrough PET/CT Technologies at SNMMI 2025 United Imaging Highlights Breakthrough PET/CT Technologies at SNMMI 2025 PR Newswire NEW ORLEANS, June 26, 2025 With ...

With innovations spanning resolution breakthroughs, intelligent solutions, and scalable system design, United Imaging presents differentiated technologies that support clinicians and researchers ...

Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s Hospital, clinical director of Nuclear Medicine at Dana-Farber Cancer Institute, and associate ...